23 results
Thumbnail

D3.316 - Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Nis-Serbia

Thumbnail

D3.305 - Pediatric and Adult Responses to Fourth-Fold Antihistamine Doses: Insights into Efficacy and Safety

Thumbnail

D3.306 - Successful treatment of severe atopic dermatitis in teenage patient with hyper-IgE syndrome (STAT3 mutation)

Thumbnail

D3.307 - Experience with Systemic Emergent Therapies for Moderate-to-Severe Atopic Dermatitis: Insights from an Allergy and Clinical Immunology Department

Thumbnail

D3.308 - Frailty in elderly with C1 Inhibitor Hereditary Angioedema: first evidence from a monocentric ITACA cohort

Thumbnail

D3.309 - Challenges in HAE therapy in children

Thumbnail

D3.310 - Hereditary angioedema (HAE) with factor XIIa mutation successfully treated with icatibant as on-demand therapy and lanadelumab for long-term prophylaxis

Thumbnail

D3.311 - Screening for Hereditary Angioedema in Pediatric Patients with Autoinflammatory Diseases and Chronic Abdominal Pain

Thumbnail

D3.312 - Lymphatic supplementation improves atopic dermatitis in dogs

Thumbnail

D3.313 - Chronic Spontaneous Urticaria and its relationship with Allergies to Aerogenic Fungi: dermographism, skin hyperreactivity, and chemical patterns of inflammation

Thumbnail

D3.314 - Sensitization Profile in Patch Tests with the Portuguese Baseline Series in the Algarve

Thumbnail

D3.315 - Airborne allergic contact dermatitis to dry shampoo

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"